Type 2 Diabetes and ADP Receptor Blocker Therapy

Journal of Diabetes Research
Matej SamošMarián Mokáň

Abstract

Type 2 diabetes (T2D) is associated with several abnormalities in haemostasis predisposing to thrombosis. Moreover, T2D was recently connected with a failure in antiplatelet response to clopidogrel, the most commonly used ADP receptor blocker in clinical practice. Clopidogrel high on-treatment platelet reactivity (HTPR) was repeatedly associated with the risk of ischemic adverse events. Patients with T2D show significantly higher residual platelet reactivity on ADP receptor blocker therapy and are more frequently represented in the group of patients with HTPR. This paper reviews the current knowledge about possible interactions between T2D and ADP receptor blocker therapy.

References

Apr 1, 1990·European Journal of Clinical Investigation·D TschoepeF A Gries
Mar 1, 1996·Journal of the American College of Cardiology·D AronsonE J Rayfield
Aug 14, 1999·Arteriosclerosis, Thrombosis, and Vascular Biology·J GeigerU Walter
Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Nov 19, 2002·JAMA : the Journal of the American Medical Association·Steven R SteinhublUNKNOWN CREDO Investigators. Clopidogrel for the Reduction of Events During Observation
Nov 7, 2003·The Journal of Biological Chemistry·Irlando Andrade FerreiraJan-Willem N Akkerman
Apr 27, 2005·Seminars in Thrombosis and Hemostasis·Pierre Savi, Jean-Marc Herbert
May 5, 2005·JAMA : the Journal of the American Medical Association·Ioannis IakovouAntonio Colombo
Nov 16, 2005·Journal of the American College of Cardiology·Paul A GurbelUdaya S Tantry
Nov 16, 2005·Journal of the American College of Cardiology·Paul A GurbelUdaya S Tantry
Dec 13, 2005·Arteriosclerosis, Thrombosis, and Vascular Biology·Irlando Andrade FerreiraJan-Willem N Akkerman
Jul 18, 2006·Journal of the American College of Cardiology·Dominick J AngiolilloAntonio Fernandez-Ortiz
Oct 16, 2007·Journal of the American College of Cardiology·Dominick J AngiolilloAntonio Fernandez-Ortiz
Nov 6, 2007·The New England Journal of Medicine·Stephen D WiviottUNKNOWN TRITON-TIMI 38 Investigators
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Nov 17, 2009·The New England Journal of Medicine·Robert A HarringtonDeepak L Bhatt
Nov 17, 2009·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PLATFORM Investigators
Nov 21, 2009·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·T KudoK Sugiyama
Sep 8, 2010·The New England Journal of Medicine·Shamir R MehtaSalim Yusuf
Nov 23, 2010·Journal of Thrombosis and Thrombolysis·M SilvanoR Padrini
Mar 17, 2011·JAMA : the Journal of the American Medical Association·Matthew J PriceUNKNOWN GRAVITAS Investigators
Apr 27, 2011·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Peter ChudýPeter Kubisz
Aug 28, 2012·The New England Journal of Medicine·Matthew T RoeUNKNOWN TRILOGY ACS Investigators
Aug 28, 2012·European Heart Journal·UNKNOWN Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)Doron Zahger
Oct 9, 2012·The American Journal of Cardiology·Guillaume CaylaGilles Montalescot
Nov 6, 2012·The New England Journal of Medicine·Jean-Philippe ColletUNKNOWN ARCTIC Investigators
Dec 20, 2012·Current Cardiology Reports·Andrew R Harper, Matthew J Price
Mar 12, 2013·The New England Journal of Medicine·Deepak L BhattUNKNOWN CHAMPION PHOENIX Investigators
Mar 16, 2013·Diabetes Care·Dimitrios AlexopoulosPeriklis Davlouros
Feb 25, 2014·The American Journal of Emergency Medicine·Matej SamošMarian Mokáň
Jul 6, 2014·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Marian FedorP Kubisz
Dec 3, 2014·Current Vascular Pharmacology·Jie TangXiao-Ping Chen
Dec 17, 2014·Pharmacology Research & Perspectives·Dany PatoineChantale Simard
May 31, 2015·Cardiovascular Diabetology·Dimitrios AlexopoulosIoanna Xanthopoulou

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass
flow cytometry

Software Mentioned

CREDO
CURE
Verify Now
Current
OASIS

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.